PORTOLA PHARMACEUTICALS INC's ticker is PTLA and the CUSIP is 737010108. A total of 153 filers reported holding PORTOLA PHARMACEUTICALS INC in Q4 2016. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $2,231,000 | +185.3% | 124,022 | +13.1% | 0.00% | +100.0% |
| Q1 2020 | $782,000 | -69.8% | 109,635 | +1.1% | 0.00% | -50.0% |
| Q4 2019 | $2,590,000 | -2.3% | 108,464 | +9.7% | 0.00% | -20.0% |
| Q3 2019 | $2,652,000 | +5.7% | 98,863 | +7.0% | 0.01% | 0.0% |
| Q2 2019 | $2,508,000 | -16.9% | 92,437 | +6.3% | 0.01% | -16.7% |
| Q1 2019 | $3,019,000 | +75.8% | 86,995 | -1.1% | 0.01% | +50.0% |
| Q4 2018 | $1,717,000 | +8.7% | 87,962 | +48.3% | 0.00% | +33.3% |
| Q3 2018 | $1,580,000 | -33.7% | 59,330 | -5.9% | 0.00% | -40.0% |
| Q2 2018 | $2,382,000 | +34.8% | 63,060 | +16.5% | 0.01% | +25.0% |
| Q1 2018 | $1,767,000 | -33.9% | 54,112 | -1.4% | 0.00% | -20.0% |
| Q4 2017 | $2,672,000 | -23.5% | 54,882 | -15.2% | 0.01% | -37.5% |
| Q3 2017 | $3,495,000 | +8.2% | 64,689 | +12.5% | 0.01% | +14.3% |
| Q2 2017 | $3,229,000 | +41.7% | 57,479 | -1.2% | 0.01% | +40.0% |
| Q1 2017 | $2,279,000 | +84.5% | 58,149 | +5.6% | 0.01% | +66.7% |
| Q4 2016 | $1,235,000 | +1.4% | 55,052 | +2.6% | 0.00% | 0.0% |
| Q3 2016 | $1,218,000 | -4.4% | 53,641 | -0.6% | 0.00% | -25.0% |
| Q2 2016 | $1,274,000 | +20.2% | 53,991 | +3.9% | 0.00% | +33.3% |
| Q1 2016 | $1,060,000 | -58.3% | 51,950 | +5.2% | 0.00% | -62.5% |
| Q4 2015 | $2,540,000 | +40.9% | 49,370 | +16.7% | 0.01% | +33.3% |
| Q3 2015 | $1,803,000 | -6.6% | 42,295 | -0.2% | 0.01% | 0.0% |
| Q2 2015 | $1,931,000 | +24.8% | 42,395 | +4.0% | 0.01% | +50.0% |
| Q1 2015 | $1,547,000 | +65.3% | 40,750 | +23.3% | 0.00% | +33.3% |
| Q4 2014 | $936,000 | +25.5% | 33,055 | +12.0% | 0.00% | +50.0% |
| Q3 2014 | $746,000 | -16.8% | 29,525 | -3.9% | 0.00% | -33.3% |
| Q2 2014 | $897,000 | +323.1% | 30,725 | +275.6% | 0.00% | +200.0% |
| Q1 2014 | $212,000 | -4.9% | 8,181 | -5.4% | 0.00% | 0.0% |
| Q4 2013 | $223,000 | -1.3% | 8,651 | +2.5% | 0.00% | 0.0% |
| Q3 2013 | $226,000 | +8.7% | 8,441 | -0.1% | 0.00% | 0.0% |
| Q2 2013 | $208,000 | – | 8,450 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fernwood Investment Management, LLC | 228,873 | $7,475,000 | 4.17% |
| PFM Health Sciences, LP | 5,326,671 | $173,969,000 | 3.54% |
| Marcus Capital, LLC | 22,950 | $750,000 | 2.76% |
| Partner Investment Management, L.P. | 72,284 | $2,361,000 | 2.55% |
| CADIAN CAPITAL MANAGEMENT, LP | 1,240,944 | $40,529,000 | 2.19% |
| HARVEY CAPITAL MANAGEMENT INC | 158,580 | $5,179,000 | 1.94% |
| SECTORAL ASSET MANAGEMENT INC | 498,412 | $16,278,000 | 1.78% |
| Everett Capital Advisors UK LLP | 551,173 | $18,001,000 | 1.52% |
| ROSENBLUM SILVERMAN SUTTON S F INC /CA | 125,210 | $4,089,000 | 1.46% |
| Atika Capital Management LLC | 113,000 | $3,691,000 | 1.26% |